跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
林 建中
教授
內科學科
內科部
電話
886 6 2353535 ext 2585
電子郵件
joshcclin
gmail
com
h-index
2455
引文
25
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2005
2026
每年研究成果
概覽
指紋
網路
專案
(7)
研究成果
(84)
類似的個人檔案
(12)
監製作品
(1)
指紋
查看啟用 Chien-Chung Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Non Small Cell Lung Cancer
92%
Lung Cancer
53%
Overall Survival
38%
Progression Free Survival
38%
Epidermal Growth Factor Receptor Kinase Inhibitor
32%
Lung Adenocarcinoma
30%
Osimertinib
24%
Brain Metastasis
22%
Chemotherapy
20%
Protein Tyrosine Kinase Inhibitor
17%
Gefitinib
16%
Combination Therapy
16%
Malignant Neoplasm
16%
STAT3 Protein
14%
Neoplasm
14%
Cohort Study
12%
Afatinib
11%
Diseases
11%
Immune Checkpoint Inhibitor
10%
Monotherapy
10%
Chronic Obstructive Lung Disease
9%
Erlotinib
9%
Interleukin 6
8%
Reactive Oxygen Metabolite
7%
Biological Marker
6%
Circulating Tumor DNA
6%
Programmed Death 1 Ligand 1
5%
Paclitaxel
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
64%
Epidermal Growth Factor Receptor
59%
Lung Cancer
33%
Progression Free Survival
33%
Overall Survival
30%
Epidermal Growth Factor Receptor Kinase Inhibitor
21%
Brain Metastasis
17%
Liquid Biopsy
16%
Combination Therapy
16%
Hazard Ratio
14%
Lymphocyte
12%
Neutrophil
12%
Tyrosine-Kinase Inhibitor
12%
Programmed Death-Ligand 1
11%
Retrospective Cohort Study
11%
Circulating Tumor DNA
10%
Lung Adenocarcinoma
9%
Thymus Cancer
9%
Osimertinib
9%
Neoplasm
9%
Afatinib
7%
Prognostic Factor
7%
Gene Mutation
7%
Biopsy Technique
6%
Non-Small Cell Lung Cancer
6%
Exon
6%
Survival Analysis
6%
Proportional Hazards Model
6%
Programmed Death 1 Ligand 1
5%
Reactive Oxygen Species
5%
Erlotinib
5%
Pembrolizumab
5%
Next Generation Sequencing
5%
Gefitinib
5%
Health Care Cost
5%
Monotherapy
5%
Immune Checkpoint Inhibitor
5%
Cohort Analysis
5%
Crizotinib
5%
Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
25%
Non-small Cell Lung Cancer Patients
20%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
19%
Overall Survival
18%
EGFR mutation
18%
Epidermal Growth Factor Receptor
16%
Hazard Ratio
14%
Progression-free Survival
13%
Non-small Cell Lung Cancer (NSCLC)
12%
Combination Therapy
10%
Signal Transducer and Activator of Transcription 3
9%
Osimertinib
9%
Survival Benefit
9%
Confidence Interval
8%
Neutrophil-to-lymphocyte Ratio
7%
Monotherapy
7%
Immune Checkpoint Inhibitors
6%
Tertiary Care Hospital
6%
Liquid Biopsy
5%
Female Lung Cancer
5%
EGFR-mutant Lung Cancer
5%
T790M mutation
5%
Prognostic Factors
5%
